Receptor tyrosine kinases inhibitors (RTKIs) targeted at VEGFR2 have proved to be attractive approaches to cancer therapy based on their ability to reduce angiogenesis and/or lymph-angiogenesis (Musumeci et al., 2012). The gene discussed is NTRK1; the disease is cancer.